help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 68, No. 2 270-275
doi:10.1210/jcem-68-2-270
Copyright © 1989 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints, Permissions and Rights
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HEIKINHEIMO, O.
Right arrow Articles by LÄHTEENMÄKI, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HEIKINHEIMO, O.
Right arrow Articles by LÄHTEENMÄKI, P.

Distribution of RU 486 and Its Demethylated Metabolites in Humans*

OSKARI HEIKINHEIMO, MAIJA HAUKKAMAA and PEKKA LÄHTEENMÄKI

Steroid Research Laboratory, Department of Medical Chemistry, University of Helsinki Helsinki, Finland

Address all correspondence and requests for reprints to Oskari Heikinheimo, Steroid Research Laboratory, Department of Medical Chemistry, University of Helsinki, Siltavuorenpenger 10A, SF-00170 Helsinki, Finland.

The concentrations of RU 486 and its demethylated metabolites were determined by RIA in samples of myometrium, abdominal adipose tissue, and serum, which were collected at hysterectomies performed 12–15 h after oral administration of 200 mg RU 486. The RU 486 concentrations in myometrium were similar in the five women studied, with a mean of 148 ± 58 (±SD) ng/g (344 ± 135 pmol/g). The adipose tissue RU 486 levels varied more, the mean concentration being 447 ± 191 ng/g (1041 ± 445 pmol/g). The serum RU 486 concentrations ranged from 175-899 ng/ml [mean, 396 ± 259 ng/mL (922 ± 603 nmol/L)]. In these women the nonproteinbound fraction of [6,7-3H]RU 486 varied from 1.4–3.1% (mean, 2.3%). The approximate concentrations of the combined monoand didemethylated metabolites of RU 486 were 1.4, 3.1, and 5.2 times higher in adipose tissue, myometrial tissue, and serum, respectively, than those of the parent RU 486. In vitro, rapid and nonsaturable accumulation of [6,7-3H]RU 486 from phosphate buffer into adipose tissue was inhibited by the addition of ofi-acid glycoprotein, the specific serum transport protein for RU 486, to the buffer medium. Accumulation of [6,7-3H]RU 486 in myometrial specimens was poor. The enterohepatic cycling of RU 486 was assessed in four normal subjects by repetitive intake of charcoal subsequent to ingestion of 200 mg RU 486. Compared to other normal subjects, the serum levels and areas under the concentration curves were lower and t1/2 values shorter in the group given charcoal, suggesting that in vivo RU 486 may be partly pooled in the enterohepatic cycle. Our studies suggest that despite the low volume of distribution and the effective serum binding of RU 486, the myometrial and adipose tissue concentrations of RU 486 and its metabolites were similar (~10–9–10–10 mol/g) after oral intake of RU 486.

* This work was supported by the Cancer Society of Finland, the Paulo Foundation, the Ford Foundation, and the Mellon Foundation. The content of this paper does not necessarily reflect the policy of any of the funding sources.

Received June 21, 1988.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
D. J. Wake, R. H. Stimson, G. D. Tan, N. Z. M. Homer, R. Andrew, F. Karpe, and B. R. Walker
Effects of Peroxisome Proliferator-Activated Receptor-{alpha} and -{gamma} Agonists on 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Subcutaneous Adipose Tissue in Men
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1848 - 1856.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
R. Leminen, T. Raivio, S. Ranta, J. Oehler, H. von Hertzen, O. A Janne, and O. Heikinheimo
Late follicular phase administration of mifepristone suppresses circulating leptin and FSH - mechanism(s) of action in emergency contraception?
Eur. J. Endocrinol., March 1, 2005; 152(3): 411 - 418.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
K. Elomaa, S. Ranta, J. Tuominen, and P. Lahteenmaki
Charcoal treatment and risk of escape ovulation in oral contraceptive users
Hum. Reprod., January 1, 2001; 16(1): 76 - 81.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
J.M. Larner, J.R. Reel, and R.P. Blye
Circulating concentrations of the antiprogestins CDB-2914 and mifepristone in the female rhesus monkey following various routes of administration
Hum. Reprod., May 1, 2000; 15(5): 1100 - 1106.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society